Navigation Links
RainDance Appoints Kelly Chief Operating Officer
Date:6/2/2008

LEXINGTON, Mass., June 2 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Roch W. Kelly as Chief Operating Officer, effective immediately.

"As RainDance solutions enter commercial development, Mr. Kelly is the ideal leader to establish our manufacturing and financial capabilities," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "With more than 20 years of experience in life sciences, he brings a proven record of successfully implementing the process and controls in these critical areas to meet the anticipated demand for our products."

Kelly joins RainDance from Synarc, Inc., where he was Vice President, Clinical Operations. Under his leadership, the operational team rapidly implemented new processes and systems that achieved a 25% improvement in efficiency. Previous positions included Chief Operating Officer and Chief Financial Officer at Protedyne, Inc., and Vice President, Clinical Operations and Worldwide Business, at PAREXEL International. He also served as Executive Director of Manufacturing Operations at Chiron Diagnostics. Kelly received a Bachelor of Science degree in finance from Miami (Ohio) University and a Master of Business Administration degree from Syracuse University.

About RainDance Technologies, Inc.

RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company's technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com.


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Announces Company Relocation and Manufacturing Startup
2. RainDance Appoints Becker Chief Commercial Officer
3. RainDance Technologies Appoints McNary President and CEO
4. IntegriChain Appoints John Bailye to Its Board of Directors
5. Trius Appoints Paul Truex to Board of Directors
6. Pelikan Technologies Appoints Denny Ware to Board of Directors
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
11. Informed Medical Communications Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):